ABVX — Abivax
Abivax (ABVX) is listed on NASDAQ.
Its activity is classified under HEALTHCARE, in the BIOTECHNOLOGY industry.
Searching for the Abivax share price, or whether to buy ABVX? This page brings together a live chart, momentum and risk scores, fresh news and community sentiment.
VAQO runs a statistical model over ABVX that reads seven technical indicators and translates them into an opportunity score and a risk score — including which factors drove them.
What ABVX is
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in advanced clinical trials targeting ulcerative colitis, utilizing a novel approach that integrates antibody-mediated therapies with proprietary compounds. Backed by a robust pipeline and an experienced scientific team, Abivax is strategically positioned to meet substantial unmet medical needs, making it an attractive prospect for institutional investors aiming to engage with the growing immunotherapy landscape.
Abivax is classified under HEALTHCARE, in the BIOTECHNOLOGY industry.
It trades on NASDAQ as a common stock.
ABVX size and valuation
At roughly $7.70B, ABVX is a mid-cap.
Earnings per share are negative at -5.84, so there is no meaningful price-to-earnings multiple to quote.
Beta is -0.23: historically it has moved less than the market.
ABVX over the past year
Over the past year ABVX has traded between $69.81 and $148.83, and the current price sits at 20% of that range.
The 50-day average is $113.54 against a 200-day average of $117.74 — the shorter average sits below the longer one, usually read as a downtrend.
The published analyst target is $164.00, 91.3% above it. A target is an aggregate of opinions, not a measurement.
How Abivax (ABVX) is trading
Abivax (ABVX) is up 1.85% at $85.73.
The session ranged from $83.63 to $86.82 — 3.7% of the share price — and the current price sits at 66% of that range.
Volume ran near 827.2K shares, about $70.9M of stock changing hands.
Traded alongside ABVX
Names traded alongside ABVX in the same sector: A (Agilent Technologies Inc), AAPG (Ascentage Pharma Group International), AARD (Aardvark Therapeutics Inc), ABCL (AbCellera Biologics Inc), ABEO (Abeona Therapeutics Inc).
What VAQO's model says about ABVX
Two statistical models run over ABVX inside the browser, reporting momentum, risk and opportunity separately. Full accuracy for both, including when it falls, is published on the model page.
Key facts
- Symbol: ABVX
- Name: Abivax
- Sector: HEALTHCARE
- Industry: BIOTECHNOLOGY
- Exchange: NASDAQ
- Instrument: Stock
ABVX — frequently asked questions
What is the market cap of ABVX?
Abivax has a market capitalisation of roughly $7.70B.
What is the 52-week range for ABVX?
ABVX has traded between $69.81 and $148.83 over the past year, with the current price at 20% of that range.
How much does ABVX stock cost today?
Abivax (ABVX) trades at $85.73, a change of +1.85% in the latest session.
Is ABVX up or down today?
ABVX is up 1.85% in the latest session, at $85.73.
What is the daily trading range for ABVX?
ABVX traded between $83.63 and $86.82 in the latest session, and currently trades at $85.73.
What is the trading volume for ABVX?
ABVX traded roughly 827.2K shares in the latest session.
Which exchange is ABVX listed on?
ABVX is listed on NASDAQ, in the HEALTHCARE sector.
Should I buy ABVX stock?
VAQO gives no buy or sell recommendations and is not an investment adviser. The ABVX figures on this page — price, range, volume and the model's scores — are there to inform your decision, not to stand in for it.
Others in HEALTHCARE
- A — Agilent Technologies Inc
- AAPG — Ascentage Pharma Group International
- AARD — Aardvark Therapeutics Inc
- ABCL — AbCellera Biologics Inc
- ABEO — Abeona Therapeutics Inc
- ABOS — Acumen Pharmaceuticals Inc
Last updated: 2026-11-08